The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies [0.03%]
急性髓系白血病的基因组景观：重新定义分类、起源和治疗策略
Nicolas Duployez,Claude Preudhomme
Nicolas Duployez
Over the past decades, the progressive identification of chromosomal abnormalities and gene mutations has transformed acute myeloid leukemia (AML) from a morphologically defined disease into a genetically stratified malignancy. The coexiste...
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications [0.03%]
急性髓系白血病的可测量残余疾病监测：技术、时机和治疗意义
Kasper J Croese,Jacqueline Cloos,Jesse M Tettero
Kasper J Croese
The detection of measurable residual disease (MRD) in acute myeloid leukaemia (AML) has emerged as one of the strongest prognostic indications of adverse outcomes across different treatment settings and disease stages, independent of baseli...
Torsten Haferlach,Jan-Niklas Eckardt,Wencke Walter et al.
Torsten Haferlach et al.
The landscape of acute myeloid leukemia (AML) diagnostics is undergoing a pivotal shift towards a transformative era, driven by the integration of artificial intelligence (AI). This review delves into the pivotal role of AI in reshaping AML...
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia [0.03%]
第十二届华德尼氏巨球蛋白血症国际研讨会的见解
Steven P Treon,Christopher J Patterson,Jeffrey Matous et al.
Steven P Treon et al.
Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with high-risk disease [0.03%]
第12届华德尼格氏巨球蛋白血症国际研讨会第三共识小组报告：高危患者管理
Prashant Kapoor,Meletios A Dimopoulos,Stephen M Ansell et al.
Prashant Kapoor et al.
The Consensus Panel 3 (CP3) of the 12th International Workshop on Waldenström macroglobulinemia (IWWM-12) has reviewed and incorporated current data to make recommendations for the management of patients with high-risk WM (HR-WM). Recogniz...
Report of consensus panel 2 from the 12th international workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia [0.03%]
第12届华氏巨球蛋白血症伴宾-内尔综合征管理国际研讨会共识专家组报告2
Shayna Sarosiek,Anne-Marie L Becking,Andrew Branagan et al.
Shayna Sarosiek et al.
Consensus panel 2 from the 12th International Workshop on Waldenstrom Macroglobulinemia was tasked with updating the guidelines on the diagnosis and management of patients with Bing-Neel syndrome (BNS). In this panel we have summarized the ...
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenström macroglobulinemia related neuropathy [0.03%]
第十二届IgM和华氏巨球蛋白血症相关神经病变患者的管理国际研讨会共识圆桌会议一报告
Shirley D&#x;Sa,Jahanzaib Khwaja,Signy Chow et al.
Shirley D&#x;Sa et al.
The IgM-related peripheral neuropathies (IgM-PN) are a group of chronic disorders characterized by the presence of monoclonal IgM that may be associated with one of several diseases affecting the peripheral nerves. In many cases, there is a...
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's Macroglobulinemia [0.03%]
第十二届瓦尔登斯特伦巨球蛋白血症国际研讨会第六共识专家组报告：瓦尔登斯特伦巨球蛋白血症转化的诊断和管理共识意见
Eric Durot,Jithma P Abeykoon,Damien Roos-Weil et al.
Eric Durot et al.
Histological transformation (HT) in Waldenström's macroglobulinemia (WM) is a rare complication and despite growing literature in the last years, no consensus recommendations exist. Consensus Panel 6 (CP6) of the 12th International Worksho...
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors [0.03%]
第12届瓦尔登斯特伦巨球蛋白血症国际研讨会共识小组5报告：共价BTK抑制剂不耐受或难治患者治疗管理建议
Jorge J Castillo,Francesco Autore,Neil L Berinstein et al.
Jorge J Castillo et al.
Over the last decade, covalent Bruton tyrosine kinase (BTK) inhibitors have become a standard option for treating patients with symptomatic Waldenström Macroglobulinemia (WM) in the frontline or relapsed settings. However, the definition o...
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics [0.03%]
骨髓瘤治愈的曙光：发病机理、建模和治疗的启示
Samir Parekh
Samir Parekh